These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 35405354)
21. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents. Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690 [TBL] [Abstract][Full Text] [Related]
22. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C. Fraile-López M; Alvarez-Navascués C; González-Diéguez ML; Cadahía V; Chiminazzo V; Castaño A; Varela M; Rodríguez M Gastroenterol Hepatol; 2023 Dec; 46(10):754-763. PubMed ID: 36716928 [TBL] [Abstract][Full Text] [Related]
23. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response. Qiu L; Xu S; Qiu Y; Liu Y; Zhang J J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735 [TBL] [Abstract][Full Text] [Related]
24. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320 [TBL] [Abstract][Full Text] [Related]
25. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response. Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658 [TBL] [Abstract][Full Text] [Related]
26. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695 [TBL] [Abstract][Full Text] [Related]
27. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707 [TBL] [Abstract][Full Text] [Related]
28. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095 [TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841 [TBL] [Abstract][Full Text] [Related]
30. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002 [TBL] [Abstract][Full Text] [Related]
31. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection. Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989 [TBL] [Abstract][Full Text] [Related]
32. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. Shirai K; Hikita H; Sakamori R; Doi A; Tahata Y; Sakane S; Kamada Y; Murai K; Nishio A; Yamada R; Kodama T; Nozaki Y; Kakita N; Ishida H; Nakanishi F; Morishita N; Imanaka K; Sakakibara M; Tatsumi T; Miyoshi E; Takehara T PLoS One; 2022; 17(12):e0279416. PubMed ID: 36542633 [TBL] [Abstract][Full Text] [Related]
33. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M; Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361 [TBL] [Abstract][Full Text] [Related]
34. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F; J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252 [TBL] [Abstract][Full Text] [Related]
35. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595 [TBL] [Abstract][Full Text] [Related]
36. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684 [TBL] [Abstract][Full Text] [Related]
37. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Ogawa E; Toyoda H; Iio E; Jun DW; Huang CF; Enomoto M; Hsu YC; Haga H; Iwane S; Wong G; Lee DH; Tada T; Liu CH; Chuang WL; Hayashi J; Cheung R; Yasuda S; Tseng CH; Takahashi H; Tran S; Yeo YH; Henry L; Barnett SD; Nomura H; Nakamuta M; Dai CY; Huang JF; Yang HI; Lee MH; Jun MJ; Kao JH; Eguchi Y; Ueno Y; Tamori A; Furusyo N; Yu ML; Tanaka Y; Nguyen MH; Clin Infect Dis; 2020 Dec; 71(11):2840-2848. PubMed ID: 31777940 [TBL] [Abstract][Full Text] [Related]
38. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Roche B; Coilly A; Duclos-Vallee JC; Samuel D Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487 [TBL] [Abstract][Full Text] [Related]
39. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C. Zhu X; Jia L; Yue M; Zhang A; Xia X; Yu R; Chen H; Huang P Sci Rep; 2024 Oct; 14(1):23760. PubMed ID: 39390065 [TBL] [Abstract][Full Text] [Related]
40. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Hagiwara H; Imai Y; Hiramatsu N; Tamura S; Yamamoto K; Oshita M; Ohkawa K; Hijioka T; Fukui H; Ito T; Doi Y; Yamada Y; Yakushijin T; Yoshida Y; Tatsumi T; Takehara T; Aliment Pharmacol Ther; 2021 Nov; 54(10):1340-1349. PubMed ID: 34618934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]